Leadership

Management has advanced AQST through regulatory and commercial milestones, but the cadence of value-creating decisions has been uneven versus better-executing specialty pharma peers.

Leadership has communicated a focused strategy around product development and commercialization, yet outcomes have depended on execution timing rather than consistently superior operating discipline.

Compared with peers that convert pipeline progress into steadier revenue and margin improvement, AQST’s leadership record shows more stop-start progress and less repeatability.

Execution

AQST has delivered meaningful product and operational progress, but the company’s modest TTM return on equity suggests management has not yet translated actions into strong capital-efficient results.

Execution has produced progress on key initiatives, yet the absence of sustained profitability improvement indicates management has not matched stronger peers on consistency.

Relative to peers with more reliable launch execution and operating leverage, AQST’s results imply competent but not yet durable execution quality.

Capital Allocation

Management has maintained a leverage profile that appears manageable, but the TTM net debt to EBITDA level indicates capital allocation has not yet created standout balance-sheet efficiency.

The company’s limited evidence of sustained earnings power suggests management has prioritized development and operating needs over demonstrably high-return capital deployment.

Versus peers that pair disciplined spending with clearer returns on invested capital, AQST’s capital allocation appears functional but not superior.

Incentives

AQST’s management incentives appear aligned to advancing clinical and commercial milestones, but the available outcomes do not yet show peer-leading value creation from those incentives.

The modest profitability profile suggests incentive structures have not fully translated into consistently stronger execution or capital discipline.

Compared with peers where compensation is more clearly tied to durable financial outcomes, AQST’s alignment looks adequate but not exceptional.

Overall Score

AQST’s management quality is moderate because leadership has delivered progress, but execution consistency and capital efficiency remain below stronger specialty pharma peers.

Score Driver: Execution Consistency